The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@cloudstrife
I am interested in having a discussion about thoughts on the Afrik-ID scheme. I do want to know why you don't like it but I keep coming back to the fact that maybe you misunderstand it. Particularly the sales aspect. here is Gus's exact words:
'They are exploring their networks…and they’re very well networked..[ ] It’s a market that we wouldn’t ordinarily be able to reach.{..] By the end of October we will know what the opportunities are..it’s a sales and marketing [exercise] , its badged AFRIk-ID, they can go in, they can go and demonstrate it and as I said looking to leverage their network across government but also in the commercial sector as well. That business is very commercially focussed like we are as well, sales are the lifeblood of any company and that’s critical for them.'
To me that's a typical reseller arrangement and there is incentive for them to make sales before the agreement expires. Not sure why you think this is a dead end. There's over 700million mobile phone users on that continent.
Because cloudstrife has the mentality of a 13 year old girl dabbling in the stock market for the first time
It's important to frame the AFRIK-ID project correctly. It is not a 4 month free trial. It's a time-limited reseller agreement given to one of the most connected people in that country. He has 4 months to land some sales in governmental organisations. Only upfront cost to CTEA would have been reskinning the app and some training, which is trivial.
Not sure why Cloudstrife keeps misrepresenting it - I've typed this up about 4 times now to help clear up the myths.
Well may be Mr & Mrs May know more on the details and reason why they put a million in the share ?
However a week has past with no news from the CEO
and pretty sure Monday morning if no 7 am update it will be another red day !!!
Is the 4 month trial he got with no revenue the only thing going at the moment is the question ...?
Have funny feeling he could be leading us down the garden path ...but could be wrong ????
Here is a transcript from Gus's interview last week:
| “Its one of those things, you can’t say too much being in a public company but there's a huge…we’ve got a lot of interest in it…..both Large scale….corporate, as well as small scale. The critical thing about that application [COV-ID] is that it is a piece of technology that has to sit within a clinical pathway. [ ] We are excited about that..there’s…and I can’t say much more than that. “
To me, this is quite telling. The way he immediately talks about the clinical pathway after saying he can't go into detail. He is alluding to the type of interest they already have - Large scale organisations and corporates that already test their staff.
If these deals materialise, they will be large scale.
Thoughts?